Bone morphogenetic proteins

Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC 50 of 9.8 nM for RGD-binding α4β1 . Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC 50 of 12.9 nMIn VitroIntegrin modulator 1 (2-10

Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC 50 of 9.8 nM for RGD-binding α4β1 . Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC 50 of 12.9 nMIn VitroIntegrin modulator 1 (2-10

Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC 50 of 9.8 nM for RGD-binding α4β1 . Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC 50 of 12.9 nMIn VitroIntegrin modulator 1 (2-10

iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to av integrins , then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and

iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to av integrins , then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and

iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to av integrins , then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and

JB002 is a myosin II inhibitor, with an IC 50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathyIn VitroJB002 show promising selectivity between cardiac and skeletal

JB002 is a myosin II inhibitor, with an IC 50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathyIn VitroJB002 show promising selectivity between cardiac and skeletal

JB002 is a myosin II inhibitor, with an IC 50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathyIn VitroJB002 show promising selectivity between cardiac and skeletal

JB002 is a myosin II inhibitor, with an IC 50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathyIn VitroJB002 show promising selectivity between cardiac and skeletal

JB061 is a nonmuscle myosin inhibitor with IC 50 s of 4.4 μM ( Cardiac muscle myosin ), 9.1 μM ( Skeletal muscle myosin ), and &gt100 μM ( Smooth muscle myosin II ), respectively. JB061 poorly decreases ATPase activity ( IC 50 &gt200 μM). JB061

JB061 is a nonmuscle myosin inhibitor with IC 50 s of 4.4 μM ( Cardiac muscle myosin ), 9.1 μM ( Skeletal muscle myosin ), and &gt100 μM ( Smooth muscle myosin II ), respectively. JB061 poorly decreases ATPase activity ( IC 50 &gt200 μM). JB061